Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-case post-marketing surveillance of Opdivo in unresectable, advanced or recurrent non-small cell lung cancer
jRCT1080223216Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Started May 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1080223216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223216.